GlassScriptPhysician profile
Norman O Moser
NPI 1093795650
$1,773.01
in general payments reported to CMS, 2019-2025
35 companies · $48.98 in 2025
The $48.98 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $242 · 2021: $83.50 · 2022: $324 · 2023: $504 · 2024: $50.55 · 2025: $48.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594 · Education: $9.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.33 |
| Education | $9.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $186.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $149.85 | 2019-2020 | |
| Corcept Therapeutics | $148.65 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $118.02 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $89.52 | 2020 | |
| Amgen INC. | $89.04 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $81.13 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.83 | 2022-2023 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $77.62 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Dexcom, INC. | $74.05 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $60.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mallinckrodt Enterprises LLC | $54.76 | 2019 | |
| Akebia Therapeutics INC | $53.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.13 | 2022 | |
| Lundbeck LLC | $37.59 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.13 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $35.35 | 2022 | |
| Fresenius USA Marketing, INC. | $34.86 | 2019 | |
| Opko Pharmaceuticals, LLC | $33.62 | 2019-2020 | |
| Bausch Health US, LLC | $28.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.20 | 2019 | |
| Daiichi Sankyo INC. | $24.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.59 | 2023 | Purified Cortrophin Gel |
| Tandem Diabetes Care, INC. | $21.88 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Inspire Medical Systems, INC. | $21.35 | 2025 | Inspire |
| Phadia US INC. | $19.03 | 2023 | Immunocap |
| Cequr Corporation | $18.10 | 2022 | |
| Amarin Pharma, INC. | $17.38 | 2022 | |
| Astellas Pharma US INC | $16.67 | 2023 | Myrbetriq |
| Zealand Pharma US, INC. | $14.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.95 | 2020 | |
| Novo Nordisk INC | $12.90 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.87 | 2020 | |
| Insulet Corporation | $11.01 | 2019 | |
| Travere Therapeutics, INC. | $9.02 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.